Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Polyphor AG
Spexis is hoping to get ColiFin, a therapy for chronic lung infections in cystic fibrosis patients, onto the US market but cannot start the necessary late-stage program without an injection of cash.
Just over three years, Polyphor's initial public offering in Switzerland raised CHF165m. Now, with just enough cash to get through the third quarter, it has been saved by a deal with US biotech EnBiotix.
Polyphor has seen its remaining asset balixafortide bite the dust and "a strategic assessment regarding the future of the company" is underway for a firm that not so long ago was seen as a rising star in the Swiss biotech sector.
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
- Drug Discovery Tools